Abstract:Background: Anxiety symptoms usually worsen depression and functional impairment. The present study was aimed to evaluate the impact of escitalopram on social function and quality of life in major depressive disorder (MDD) patients with anxiety symptoms. Patients and methods: Adult MDD patients with functional impairment (Sheehan Disability Scale [SDS] score >= 9) and anxiety symptoms (Hamilton Anxiety Rating Scale [HAM-A] score >= 14) received escitalopram (10-20 mg/day) for 8 weeks. Symptom status was assessed by SDS, Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form, Montgomery-Asberg Depression Rating Scale (MADRS), HAM-A, and Quick Inventory of Depressive Symptomatology Self Report scales. Safety was evaluated by treatment-emergent adverse events (TEAEs). Results: Overall, 208 (79.7%) of 261 enrolled patients completed the 8-week treatment. Mean (SD) SDS and Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form total scores were 17.4 (5.87) and 39.3 (14.43) at baseline, which improved to 7.6 (6.71) and 61.6 (15.80), respectively, at week 8. Totally, 59.2% of patients achieved functional remission (SDS <= 6) and 61.7% of patients achieved depression remission (MADRS <= 10) at week 8; 48.1% of patients achieved both functional and depression remission (SDS <= 6 and MADRS <= 10). The change in SDS total score was positively correlated with the change in MADRS and HAM-A total scores at each visit. Patient's baseline SDS score was related with depression score (regression coeflicient=0.40582, y=0.0005); remission of SDS was statistically related to a reduction of week 2 and week 6 HAM-A score (p<0.0001) and reduction of MADRS score (p<0.0001). Overall, 25.7% of patients reported r 1 TEAEs. Most frequently reported TEAEs were nausea (5.8%), diarrhea (2.3%), and dizziness (2.7%). Most TEAEs were mild to moderate in severity. Four patients reported serious TEAEs, two patients reported suicide attempts, and one patient completed suicide. Conclusion: Escitalopram (10-20 mg/day) treatment was efficacious in reducing depression, improving social function, and quality of life in MDD patients with anxiety symptoms. No new safety signals were identified.

Comparison of Escitalopram with Citalopram in Treatment of Depression: a Randomized, Double-Blind, Multicenter Study

Escitalopram Vs Citalopram: a Parallel Controlled Study for Depression

A comparative study of treatment of depression:Mirtazapine vs.fluoxepine

Randomized,multicenter,double blind comparative trial of reboxetine in the treatment of depression with or without anxiety

Citalopram and escitalopram in the treatment of major depressive disorder: a pooled analysis of 3 clinical trials.

Comparative Efficacy and Safety of Escitalopram versus Desvenlafaxine in Postmenopausal Women with Depression and Anxiety: A Randomized, Open-Label, Comparative Trial

Efficacy of Escitalopram Monotherapy in the Treatment of Major Depressive Disorder

Efficacy and Safety of Escitalopram in Treatment of Severe Depression in Chinese Population.

Efficacy and Safety of Bupropion Hydrochloride Extended-Release Versus Escitalopram Oxalate in Chinese Patients with Major Depressive Disorder: Results from a Randomized, Double-Blind, Non-Inferiority Trial.

Escitalopram and sertraline in treatment of depression with anxiety

Citalopram in the Treatment of Depressive Disorders: an Open Label, Multicenter Study in China

Clinical effects of escitalopram in the treatment of senile depression

Acute Efficacy and Safety of Escitalopram Versus Desvenlafaxine and Vortioxetine in the Treatment of Depression With Cognitive Complaint: A Rater-Blinded Randomized Comparative Study

The Efficacy and Safety of Citalopram in Treatment of Depression: a Multi-Center, Open-Label Study

Escitalopram versus other antidepressive agents for major depressive disorder: a systematic review and meta-analysis

Comparison of Reboxetine with Fluoxetine in Treatment of Depression: a Randomized, Double-Blind, Multicenter Study

Effect observation of escitalopram combination with ziprasidone in the treatment of treatment-resistant depression

A Randomized and Double-Blind Comparison with Reboxetine and Citalopram in Patients with Retardant Depressive Disorder

Citalopram versus Clomipramine for the Treatment of Panic Disorders-a Double-blind Randomized Study

Pharmacokinetics and bioequivalence study of escitalopram oxalate formulations after single-dose administration in healthy Chinese male volunteers

Safety and effectiveness of escitalopram in an 8-week open study in Chinese patients with depression and anxiety.